40 results about "Sphingomyelin" patented technology

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

The invention introduces novel chemical modifications to sphingomyelin and ceramide molecules, making them readily available for targeted staining and detection techniques, such as click chemistry.

The invention relates to a pharmaceutical composition consisting of a liposomal formulation of a phospholipid component and an aqueous phase, wherein the phospholipid component is selected from the group consisting of phosphatidylcholine, and sphingomyelin, and wherein the phospholipid component comprises a saturated or mono-unsaturated (Z / cis) fatty acid having 14 to 20 carbon atoms. The invention further relates to the use of the pharmaceutical composition in treatment of a condition associated with presence of lipopolysaccharide (LPS), particularly endotoxemia.

The present invention provides a nutritional composition comprising milk phospholipids and egg phospholipids, particularly suitable as a nutritional composition for infants, also as a nutritional support product for pregnant women and as a nutritional supplement for the elderly, in which phosphatidylcholine and sphingomyelin and hence choline are also highly correlated. The invention provides a nutritional composition containing choline with high bioavailability.

The present invention relates to the field of nutritional compositions, methods of providing nutritional compositions and uses thereof. More particularly, the present invention relates to a ready-to-eat powdered infant formula or ready-to-eat powdered growth formula exhibiting desirable gastric digestion characteristics. There is provided a nutritional composition comprising casein, whey protein comprising alpha-lactalbumin (aLac) and beta-lactoglobulin (bLac), and protein-coated fat droplets wherein the composition has a protein content of from 5% to 20% (w / w) based on total solids; the bLac content is at least 3% (w / w) based on the total protein level, and the aLac + bLac content is at least 25% (w / w) based on the total protein level; the fat content is in the range of 10% to 50% (w / w) based on total solids; the fat droplets are coated with an average protein load of 2 to 10 mg / m2, and wherein the weight ratio of casein: (aLacc + bLac) on the fat droplets is at least 4 times the weight ratio of casein: (aLacc + bLac) in the total composition; the level of sphingomyelin per 100 g of the composition is between 70 mg and 200 mg; the level of phospholipids per 100 g of the composition is between 280 mg and 950 mg.

The invention relates to a lipid nutritional composition, a product comprising the same and application of the lipid nutritional composition in preparation of a product for promoting structural development of neural stem cells. The lipid nutritional composition comprises: docosahexaenoic acid and / or a metabolic precursor thereof; arachidonic acid and / or a metabolic precursor thereof; and a population of phospholipids consisting of phosphatidylcholine (PC) and / or a metabolic precursor thereof, phosphatidylserine (PS) and / or a metabolic precursor thereof, phosphatidylethanolamine (PE) and / or a metabolic precursor thereof, phosphatidylinositol (PI) and / or a metabolic precursor thereof, and sphingomyelin (SM) and / or a metabolic precursor thereof; wherein the ratio of the molar equivalents of arachidonic acid to the molar equivalents of docosahexaenoic acid, ARA / DHA, is 1-2: 1; and the ratio of the total molar equivalents of the phospholipid population to the molar equivalents of docosahexaenoic acid, PHL / DHA, is 1-8: 1.

The present invention provides a nutritional composition especially well suited as an infant nutritional composition, but also as a nutritional support product for pregnant women and as senior nutritional supplement, where phosphatidylcholine and sphingomyelin, and thus choline, also are highly relevant. The present invention provides a nutritional composition which contains choline of high bio-availability.

A method of treating Parkinson's disease in a subject in need thereof. The method comprises administering a liposomal composition, comprising sphingomyelin in a lipid bilayer and a therapeutically effective amount of GM1, to the subject.

The invention discloses a phospholipid hydrophilic chromatographic separation and evaporative light scattering detection method suitable for liquid milk, milk powder and milk source raw materials. The method comprises the following steps: preparing a sample solution from a sample to be detected; extracting the sample solution by using a solution of chloroform and methanol to obtain subnatant as extract liquor; adding a saturated salt solution into the extract liquor for chromatographic purification, and taking separated lower clear liquid as purified liquid; preparing the purified liquid into a sample introduction liquid; and determining the phospholipid content in the sample injection solution by using a liquid chromatography-evaporative light scattering detector. In the detection method, a sample solution is extracted by using a solution of chloroform and methanol, and a saturated salt solution is added into an extraction solution for chromatographic purification, so that chromatographic peaks are not interfered, and various phospholipids in food can be accurately measured at the same time; the method can be used for simultaneously determining phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidylserine and phosphatidylinositol in food, and has the advantages of simplicity, rapidness, accuracy, low detection limit and high sensitivity.

A persistent encapsulation structure capable of preventing the degradation of bioactive substances, which encapsulation structure comprises a variety of encapsulation structure bodies (10), characterized by that the respective encapsulation structure body (10) has a polysaccharide structure (11) by which a plurality of bioactive substances (12) are encapsulated, wherein the bioactive substance (12) is selected from a group consisting of a bioactive fatty substance (121) and a bioactive non-fatty substance (122); that the polysaccharide structure (11) comprises at least one polysaccharide, wherein the at least one polysaccharide is first thoroughly mixed, then sheared at high pressure or homogenized at high speed and finally atomized dried, such that the polysaccharide structure (11) forms branched polysaccharides and linear polysaccharides which form a multitude of network structures; that the bioactive fatty substance (121) is selected from a group consisting of glycerophospholipids, sphingophospholipids, gangliosides, L-α- / glycerylphosphorylcholines, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidylserines, phosphatidic acids, phosphatidylglycerol, ceramides, glucocerebrosides, glycolipids, cholesterols and fatty acid substances; and that the bioactive nonfatty substance (122) is selected from a group of coenzymes, vitamins, carotenes, carotenoids, curcuminoids, curcumin, curcumin extract, polyphenols, saponins, glycosides, terpenoids, ergothioneine, minerals, acid substances, functional polysaccharides, carbohydrates, functional proteins, peptides, amino acids and their derivatives.

The invention relates to the technical field of biological pharmacy, and discloses a mesenchymal stem cell exosome enhancer and a preparation method thereof, the enhancer is composed of purified mesenchymal stem cell exosome, a functional lipid complex, cytokine sustained release microspheres, a targeting modifier, a stabilizer and a penetration enhancer according to specific parts by weight. The preparation method comprises the following steps: obtaining a high-activity exosome by combining ultracentrifugation with size exclusion chromatography purification; preparing a functional lipid complex composed of cholesterol, sphingomyelin and phosphatidylserine to promote membrane fusion; preparing a sodium alginate-chitosan sustained release microsphere loaded with a basic fibroblast growth factor and a transforming growth factor-beta1; synthesizing an RGD peptide modified hyaluronic acid targeting modifier; and finally, mixing the components, filtering and sub-packaging. The quality fluctuation risk of subsequent preparation preparation is reduced, and it is guaranteed that the final reinforcing agent product has a highly uniform structure.

The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells. Injected intravenously, liposome mixtures prevented death of laboratory mice infected with lethal doses of Staphylococcus aureus or Streptococcus pneumoniae.

The invention discloses lactobacillus crispatus CCFM1462 and application of a metagen of the lactobacillus crispatus CCFM1462 in promoting skin ceramide synthesis by regulating a sphingomyelinase pathway, and belongs to the technical field of microorganisms and medicines. The lactobacillus crispatus CCFM1462 provided by the invention can effectively improve the content of ceramide in the aspects of external use and oral administration. According to the application disclosed by the invention, it is found that a metagen (fermented supernatant CCFM1462-S) prepared by oral administration of lactobacillus crispatus CCFM1462 can promote expression of sphingomyelinase, so that a sphingomyelinase pathway in a ceramide synthesis process is regulated and controlled, and rapid supplement of ceramide is realized. Therefore, the lactobacillus crispatus plays a crucial role in solving the problem that ceramide needs to be supplemented emergently after skin irritation, has a huge application prospect when being applied to oral or external medicines, and is used for transient stress repair of skin.

The invention discloses staphylococcus epidermidis CCSM009 for repairing a skin barrier and a metagen of the staphylococcus epidermidis CCSM009, and belongs to the field of microbial technologies and medicines. The staphylococcus epidermidis CCSM009 and the metagen thereof provided by the invention have a good barrier function repairing effect and application prospect in the aspect of external use, and are specifically shown as follows: the activity of damaged HaCaT cells is improved in vitro, and the expression of gene levels and protein levels in the aspects of functional proteins and structural proteins after damage is improved; meanwhile, sphingomyelinase 1 and tissue kininolase 7 (KLK7) are improved, and it is clear that the bacterium performs up-regulation of skin barrier related proteins and enzymes through an AHR-OVOL1 pathway. Therefore, the metagen of the staphylococcus epidermidis CCSM009 has a huge application prospect in preparation of cosmetics or medicines for repairing the skin barrier.

The application discloses a p-hydroxycinnamaldehyde modified sphingomyelin liposome and application thereof in anti-MRSA infection. The p-hydroxycinnamaldehyde is bonded with the sphingomyelin through a two-step esterification reaction to obtain a bonding product sphingomyelin-p-hydroxycinnamaldehyde, and the p-hydroxycinnamaldehyde modified sphingomyelin liposome is prepared through a film hydration method. The liposome provided by the application is spherical, and the particle size distribution is uniform. The sphingomyelin component in the liposome can effectively neutralize the exotoxin of MRSA, and relieve the damage of the exotoxin of MRSA to normal cells of the body. The p-hydroxycinnamaldehyde in the liposome can induce the M0 type and M2 type macrophages in the body to polarize into M1 type macrophages with stronger phagocytosis and killing ability, relieve the immunosuppression caused by MRSA infection, and enhance the clearance ability of the macrophages to MRSA. The liposome provided by the application has application prospects in the preparation of drugs or preparations for treating diseases caused by MRSA infection.

The invention discloses a Mycomonas rosae CCSM007 strain separated from human skin and capable of improving skin health and a metagen of the Mycomonas rosae CCSM007 strain, and belongs to the field of microbial technologies and medicines. The myxomonas rosae CCSM007 provided by the invention has a good barrier function repairing effect and application prospect in the aspect of external use, and the application prospect is specifically shown as follows: the activity of damaged HaCaT cells is improved in vitro, the expression of gene levels and protein levels in the aspects of functional proteins and structural proteins after damage is improved, and meanwhile, the expression of sphingomyelinase 1 (SMPD1) is improved. The metaplast of the myxomonas rosae has a huge application prospect in preparation of cosmetics or medicines for repairing skin barriers.

The invention introduces novel chemical modifications to sphingomyelin and ceramide molecules, making them readily available for targeted staining and detection techniques, such as click chemistry.

Novel compounds useful in the synthesis of sphingomyelins, for example N-palmitoyl-D-erythro-sphingomyelin, novel processes for making sphingomyelins using the novel compounds, preparations of sphingomyelin made by the processes, and compositions comprising sphingomyelins.

The invention discloses a skin-derived staphylococcus coriolis CCSM006 for improving skin health based on multiple targets and a metagen thereof, and belongs to the field of microbial technologies and medicines. The staphylococcus coriolis CCSM006 provided by the invention shows a remarkable barrier repair effect in the aspect of external use, and the remarkable barrier repair effect is specifically shown as follows: in an in-vitro experiment, the activity of damaged HaCaT cells can be promoted, the gene and protein expression levels of functional proteins and structural proteins after damage are improved, and meanwhile, the expression of sphingomyelinase 1 (SMPD1) and tissue kinin enzyme 7 (KLK7) is remarkably improved. Research finds that the strain regulates the expression of skin barrier related proteins and enzymes through an AHR-OVOL1 pathway. The staphylococcus coriolis metagen has a wide application prospect in the field of cosmetics or medicines.

The invention discloses a broad-spectrum targeted virulence factor response type phototherapy nano-particle, a preparation method and application of the broad-spectrum targeted virulence factor response type phototherapy nano-particle in preparation of antibacterial drugs. The nano-particle comprises a shell PSP formed by heterozygosis of lipid PS and a platelet cell membrane P, and the lipid PS is synthesized with phosphatidylcholine through sphingomyelin; a photosensitizer entrapped in the lipid PS bilayer; the photosensitizer and the perfluorocarbon are entrapped in the shell PSP, and the perfluorocarbon carries oxygen. According to the present invention, with the application of the compound, the broad-spectrum targeting of gram-negative bacteria and gram-positive bacteria can be achieved, the treatment accuracy can be improved, the dual functions of virulence factor neutralization and antibacterial effect enhancement can be provided, and the phototherapy antibacterial treatment effect can be significantly improved.

The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.

The application discloses a combined metabolic marker and detection kit for mitochondrial purity evaluation, the marker comprises phosphatidylcholine PC 34:0 (16:0 / 18:0), sphingomyelin SM 34:1;2O (d18:1;2O / 16:0), sphingomyelin SM 44:2;2O (18:1;2O / 24:1) and hexosylceramide HexCer 42:2;2O (d18:1;2O / 24:1), and is used for judging the new application and kit of mitochondrial purity of mitochondria extracted by a mitochondrial extraction method. The application judges the mitochondrial purity extracted by the method by detecting the relative concentrations of four lipid metabolites in the mitochondrial sample, calculating a combined marker variable P based on a binary logistic regression equation and determining a cut-off value. The kit can realize high-sensitivity and high-efficiency detection of the four small molecule metabolites, and has the characteristics of low detection cost and good repeatability.

The application discloses an enzyme catalysis production method of phosphatidylserine, and belongs to the technical field of biology, and specifically comprises the following steps: in a reaction system of [BMIM][BF4] aqueous solution, taking natural phosphatide containing phosphatidylcholine and cephalin as raw materials, adding L-serine, calcium salt and phospholipase D to carry out a transacylation reaction. By introducing specific proportions of cephalin (4%-10%, preferably 6%-8%) and sphingomyelin (5%-10%), in combination with the [BMIM][BF4] ionic liquid system, the application realizes efficient and high-purity (purity>79.6%, yield>76.4%) production of PS, and completely solves the problem that yield and purity cannot be considered simultaneously in the traditional process.

We demonstrate that supplementation with resistant potato starch (RPS) influences the circulating levels of retinol, alpha-tocopherol, choline, and the choline-derived phospholipid sphingomyelin in serum. Levels of the toxic microbially transformed choline metabolites trimethylamine and trimethylamine oxide did not increase, suggesting that RPS may be an e ective way to enhance choline uptake without promoting increased toxic metabolite production. Increased hydroxysphingomyelin levels in RPS consuming individuals are particularly intriguing given the role these metabolites play in myelin.

An object of the present invention is to provide a method for easily producing sphingomyelins.SOLUTION: A phosphocholine-forming agent represented by general formula (1) is reacted with ceramides represented by general formula (2). According to the present invention, sphingomyelins represented by the following general formula (3) can be produced by a one step reaction. (In the formula, A represents a five membered nitrogen-containing heterocyclic structure, and Ra and Rb each independently represent a saturated or unsaturated hydrocarbon group which may be substituted.). ) SELECTED DRAWING: None

The invention relates to the technical field of biological medicine detection, in particular to application of a serum sphingomyelin marker in preparation of a product for diagnosing late-onset neuromyelitis optica pedigree diseases, and the serum sphingomyelin marker comprises at least one of SM (d18: 1 / 16: 0), SM (d18: 2 / 20: 1) and SM (d18: 2 / 22: 1). The three serum sphingomyelin markers screened and found by the invention have high sensitivity and specificity in diagnosis of late-onset neuromyelitis optica pedigree diseases. Compared with biological samples such as cerebrospinal fluid and the like, the serum sample is easy, convenient, rapid and noninvasive to obtain, has good clinical accessibility and patient compliance, and is more suitable for developing disease screening or auxiliary diagnosis tools convenient to popularize. The serum-based biomarker research provided by the invention has wide clinical application prospect and industrialization value.

The invention discloses a method for analyzing milk fat globule membrane phospholipids of different milk sources based on Q-TOF-MS / MS, and belongs to the technical field of detection. The invention provides a Q-TOF-MS / MS (Quantitative Time of Flight Mass Spectrometry / Mass Spectrometry)-based method for analyzing milk fat globule membrane phospholipids of different milk sources in order to solve the problem of lack of difference of lipid molecules in MFGM of different milk sources based on a lipidomics system in the prior art, and through a Q-TOF-MS / MS analysis technology, full categories of glycerophospholipids and sphingomyelin in MFGM of breast milk, cow milk and goat milk are quantitatively detected at one time; by combining multi-factor statistics-single factor variance analysis, differential phospholipids are accurately screened, a unique lipid molecule fingerprint spectrum of each milk source is established, and the spectrum can directly guide directional addition of infant formula milk powder MFGM, so that the phospholipid composition is close to breast milk on a molecular level, and the lipid molecule fingerprint spectrum has the advantages of high lipid molecule fingerprint spectrum and high lipid molecule fingerprint spectrum. The defects of existing formula phospholipid spectrum mismatch, structure deficiency, data blank and efficacy prediction disjunction are overcome.

This invention provides a herbal hydrogel eye patch for preventing and treating myopia in adolescents and its preparation method. The patch includes at least a hydrogel layer loaded with herbal extracts. The herbal extracts include the following ingredients: Salvia miltiorrhiza, Angelica sinensis, Lycium barbarum, Buddleja officinalis, Ligusticum chuanxiong, Lonicera japonica, Vaccaria segetalis, Astragalus membranaceus, and Glycyrrhiza uralensis. The matrix of the hydrogel layer includes the following ingredients in parts by weight: poloxamer 20-25 parts, sphingomyelin 2.0-4.0 parts, sodium glycerophosphate 1.5-2.0 parts, sodium phytate 0.5-0.8 parts, modified chitosan 1.0-2.0 parts, and sodium pyrrolidone carboxylate 0.5-1.0 parts. This herbal hydrogel eye patch for preventing and treating myopia in adolescents can improve the discomfort symptoms of myopia patients and effectively prevent and treat myopia in adolescents.

The invention discloses an anti-allergic inflammation composition and a preparation method and application thereof, the active ingredients of the composition comprise sphingomyelin and beta-arbutin, and the concentration ratio of the sphingomyelin to the beta-arbutin is 1: 2-2: 1. The sphingomyelin and beta-arbutin composite formula has a huge application prospect in the development of anti-allergic inflammation products (such as respiratory mucosa protective agents, skin anti-inflammatory care products, allergy prevention dietary supplements and the like).